70 related articles for article (PubMed ID: 7972219)
1. Autocrine regulation of neuroblastoma cell growth and differentiation by vasoactive intestinal peptide.
Pence JC; Kerns BJ; Shorter NA
Prog Clin Biol Res; 1994; 385():269-74. PubMed ID: 7972219
[No Abstract] [Full Text] [Related]
2. The autocrine function of vasoactive intestinal peptide on human neuroblastoma cell growth and differentiation.
Pence JC; Shorter NA
Arch Surg; 1993 May; 128(5):591-5. PubMed ID: 8387768
[TBL] [Abstract][Full Text] [Related]
3. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.
Isobe K; Kaneko M; Kaneko S; Nissato S; Nanmoku T; Takekoshi K; Okuda Y; Kawakami Y
Regul Pept; 2004 Dec; 123(1-3):29-32. PubMed ID: 15518890
[TBL] [Abstract][Full Text] [Related]
4. New nonradioactive technique for vasoactive intestinal peptide-receptor-ligand-binding studies.
Haberl I; Habringer DS; Andreae F; Artl A; Mosgoeller W
Ann N Y Acad Sci; 2006 Jul; 1070():313-6. PubMed ID: 16888184
[TBL] [Abstract][Full Text] [Related]
5. Regulatory peptides in neuronal neoplasms of the central nervous system.
Giangaspero F; Burger PC; Budwit DA; Usellini L; Mancini AM
Clin Neuropathol; 1985; 4(3):111-5. PubMed ID: 2861927
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
Petkov V; Mosgoeller W; Ziesche R; Raderer M; Stiebellehner L; Vonbank K; Funk GC; Hamilton G; Novotny C; Burian B; Block LH
J Clin Invest; 2003 May; 111(9):1339-46. PubMed ID: 12727925
[TBL] [Abstract][Full Text] [Related]
7. Autoregulation of neuroblastoma growth by vasoactive intestinal peptide.
Pence JC; Shorter NA
J Pediatr Surg; 1992 Aug; 27(8):935-43; discussion 944. PubMed ID: 1328588
[TBL] [Abstract][Full Text] [Related]
8. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
9. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
10. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
11. [Acute diarrhea as a leading symptom of ganglioneuroblastoma].
Schaarschmidt K; Morcate JJ; Schleef J; Saxena A; Willital GH
An Esp Pediatr; 1998 Nov; 49(5):519-22. PubMed ID: 9949599
[No Abstract] [Full Text] [Related]
12. Further studies on the interaction between vasoactive intestinal peptide and neuroblastoma cell lines.
Pence JC; Shorter NA
Prog Clin Biol Res; 1991; 366():375-81. PubMed ID: 1829837
[No Abstract] [Full Text] [Related]
13. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cell proliferation in human neuroblastoma: comparison with other prognostic factors.
Mejía C; Navarro S; Pellín A; Ruíz A; Castel V; Llombart-Bosch A
Oncol Rep; 2003; 10(1):243-7. PubMed ID: 12469176
[TBL] [Abstract][Full Text] [Related]
16. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas.
Vertongen P; Devalck C; Sariban E; De Laet MH; Martelli H; Paraf F; Hélardot P; Robberecht P
J Cell Physiol; 1996 Apr; 167(1):36-46. PubMed ID: 8698838
[TBL] [Abstract][Full Text] [Related]
17. Characterization of somatostatin receptors on human neuroblastoma tumors.
O'Dorisio MS; Chen F; O'Dorisio TM; Wray D; Qualman SJ
Cell Growth Differ; 1994 Jan; 5(1):1-8. PubMed ID: 8123588
[TBL] [Abstract][Full Text] [Related]
18. Ageing and the diurnal expression of mRNAs for vasoactive intestinal peptide and for the VPAC2 and PAC1 receptors in the suprachiasmatic nucleus of male rats.
Kalló I; Kalamatianos T; Piggins HD; Coen CW
J Neuroendocrinol; 2004 Sep; 16(9):758-66. PubMed ID: 15344914
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
Van Rampelbergh J; Juarranz MG; Perret J; Bondue A; Solano RM; Delporte C; De Neef P; Robberecht P; Waelbroeck M
Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
[TBL] [Abstract][Full Text] [Related]
20. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.
Giannini G; Kim CJ; Di Marcotullio L; Manfioletti G; Cardinali B; Cerignoli F; Ristori E; Zani M; Frati L; Screpanti I; Guilino A
Br J Cancer; 2000 Dec; 83(11):1503-9. PubMed ID: 11076660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
